Advisory Services Network’s Edgewise Therapeutics EWTX Stock Holding History

Advisory Services Network’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$496K	Buy	12,209 +12,058	+7,985%	+$416K	0.01%	1409
2026 Q1	$4.77K	Buy	+151	New	+$4.35K	﹤0.01%	3876
2025 Q4	–	Sell	-151	Closed	-$2.46K	–	2591
2025 Q3	$2.46K	Buy	+151	New	+$2.14K	﹤0.01%	3749

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Advisory Services Network's EWTX Position: Q2 2026 in Review

Advisory Services Network increased its Edgewise Therapeutics (EWTX) stake by 7,985% in Q2 2026, buying an estimated $416K and bringing the position to 12,209 shares worth $496K. The position accounts for 0.01% of the portfolio, ranked #1409.

Advisory Services Network first reported a position in EWTX in Q3 2025 and has held it in 3 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Advisory Services Network held 12,209 shares of Edgewise Therapeutics worth $496K as of Q2 2026.
Advisory Services Network bought 12,058 Edgewise Therapeutics shares in Q2 2026, an estimated $416K.
Edgewise Therapeutics made up 0.01% of Advisory Services Network's portfolio in Q2 2026, its #1409 holding.
Advisory Services Network first reported a position in Edgewise Therapeutics in Q3 2025 and has held it in 3 quarters since.
225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Advisory Services Network's 13F filing for Q2 2026, filed 12 Aug 2026.